Alnylam CEO Touts Advances with Lipid, Conjugate Delivery Approaches
June 02, 2011
Alnylam CEO Touts Advances with Lipid, Conjugate Delivery Approaches
During a presentation to investors last week, CEO John Maraganore highlighted the company's collaborations with Massachusetts Institute of Technology and AlCana, but notably made no mention of partner Tekmira Pharmaceuticals, which sued Alnylam earlier in the year.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Alnylam to Cut a Third of Its Staff on Heels of Pipeline Reorganization
January 26, 2012 / Gene Silencing News - Tekmira Alleges Theft of Confidential Documents by AlCana
November 17, 2011 / Gene Silencing News - In Ongoing Suit, Alnylam Claims Partner Tekmira Misappropriated Trade Secrets
June 30, 2011 / Gene Silencing News - Tekmira Provides Pipeline Update, Eyes Agricultural Market
February 14, 2013 / Gene Silencing News - Alnylam Reports Positive Phase I Data on ATTR Drug; Sees Pfizer Drug Setback as FDA Guide
July 19, 2012 / Gene Silencing News